Research-Focused Blog Posts
Our blog posts offer concise, expert commentary on the latest developments in VHH technology. From new research findings to industry updates and practical tips, each article is written to inform and support your scientific work.
Lipid Nanoparticles for Drug Delivery: Precision Targeting Beyond the Liver — and the Role of VHHs
Lipid nanoparticles are central to nucleic acid delivery but remain constrained by liver tropism and limited cell specificity. This article examines how VHH antibodies enable receptor-mediated targeting, supporting extrahepatic delivery while maintaining manufacturability and scalability. Read more
VHH and the blood–brain barrier challenge
The blood–brain barrier remains a critical bottleneck in CNS drug delivery, excluding nearly all biologics. VHH antibodies offer a practical route forward, combining small size, stability, and engineering flexibility to enable receptor-mediated transport into the brain. This article examines transport mechanisms, emerging applications, and how synthetic VHH libraries support the development of brain-penetrant biologics. Read more
Machine Learning and Artificial Intelligence in Antibody Discovery: Breakthroughs, Blind Spots, and the Road Ahead
AI won’t eliminate antibody discovery wet-lab workflows. However, high-throughput clean empirical discovery plus ML-driven iterations have the potential to make discovery more predictable, faster to converge, and easier to scale. Read more
How VHHs Can Redefine the Next Generation of ADCs
Antibody–drug conjugates (ADCs) remain one of the most promising modalities in oncology, but the next generation demands smarter, more adaptable scaffolds. Single-domain antibodies bring precisely that: offering high affinity and stability in a compact, engineerable scaffold. By merging these two platforms, we get an antibody framework that can address long-standing bottlenecks in the industry. Read more
The Proteins We Work With: A Guide to Supported Antigen Materials
A technical overview of how in vitro discovery platforms support VHH antibody and peptide discovery across challenging protein classes, from soluble enzymes to membrane proteins, toxic antigens and complex multimeric targets, using tailored antigen presentation strategies. Read more
Building Smarter Therapeutics with VHH Bolt-Ons
VHH antibodies provide modular, high-performance components that can enhance biologics across multiple modalities. From albumin-binding half-life extension to bi-/multi-specific engineering and intracellular TPD, VHH bolt-ons enable more flexible, efficient and targeted therapeutic design. This article examines the key applications, design considerations e case studies that illustrate how VHH domains support next-generation engineered biologics. Read more
CIS Display™ vs. Phage Display: Choosing the Right Fit for VHH or Peptide Discovery
Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on their underlying techniques, important benefits, and suitable applications. Read more
NGS in Antibody Discovery: How Deep is Your Sequence?
Next-generation sequencing is redefining antibody discovery. From validating library diversity to uncovering rare binders and powering AI-driven design, NGS offers additional insights that enhance VHH antibody discovery and selection. Read more
Unlocking Hard-to-Drug Targets: How VHH Antibodies Overcome Drug Discovery Barriers
Today, the term ‘undruggable’ is being redefined. Advances in membrane protein solubilization, allosteric modulation, and therapeutic viral vectors have led to proof that these targets can be tackled. Read more
A Competitive and Ethical Future in Discovery
Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise binders against a target antigen. However, emerging synthetic antibody library technologies now allow scientists to bypass animal immunization by using in silico designed vast libraries of human or humanized antibody fragments.